Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Losmapimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Fulcrum stock slumps after muscle disorder drug fails in late-stage study
    Fulcrum stock slumps after muscle disorder drug fails in late-stage study

    13 Sep 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/fulcrums-muscle-disorder-drug-fails-late-stage-study-2024-09-12/

    REUTERS
    13 Sep 2024
    Share Share
    Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
    Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug

    14 May 2024

    // Jonathan Gardner BIOPHARMADIVE

    https://www.biopharmadive.com/news/sanofi-fulcrum-muscular-dystrophy-drug-deal/715893/

    Jonathan Gardner BIOPHARMADIVE
    14 May 2024
    Share Share
    Fulcrum Losmapimod FSHD Study Published In Lancet Neurology
    Fulcrum Losmapimod FSHD Study Published In Lancet Neurology

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2877769/0/en/Fulcrum-Therapeutics-Announces-Publication-of-Results-from-Phase-2b-Clinical-Trial-of-Losmapimod-in-Facioscapulohumeral-muscular-dystrophy-ReDUX4-in-The-Lancet-Neurology.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share
    Fulcrum Announces Completion of Enrollment in the Phase 3 Trial of Losmapimod
    Fulcrum Announces Completion of Enrollment in the Phase 3 Trial of Losmapimod

    07 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/07/2739280/0/en/Fulcrum-Announces-Completion-of-Enrollment-in-the-Phase-3-REACH-Clinical-Trial-of-Losmapimod-in-Facioscapulohumeral-Muscular-Dystrophy-FSHD.html

    GLOBENEWSWIRE
    07 Sep 2023
    Share Share
    Fulcrum CEO leaves for new opportunity, company starts search for replacement
    Fulcrum CEO leaves for new opportunity, company starts search for replacement

    04 Jan 2023

    // ENDPTS

    https://endpts.com/fulcrum-ceo-leaves-for-new-opportunity-company-starts-search-for-replacement/

    ENDPTS
    04 Jan 2023
    Share Share
    Fulcrum Enrolls 1st Patient in Pivotal Global PIII Trial of Losmapimod for FSHD
    Fulcrum Enrolls 1st Patient in Pivotal Global PIII Trial of Losmapimod for FSHD

    05 Jul 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/07/05/2473844/0/en/Fulcrum-Therapeutics-Enrolls-First-Patient-in-Pivotal-Global-Phase-3-Clinical-Trial-of-Losmapimod-for-Facioscapulohumeral-Muscular-Dystrophy-FSHD.html

    GLOBENEWSWIRE
    05 Jul 2022
    Share Share